Axitinib (AG-013736)

DRUG13 trials

Sponsors

Pfizer, University Health Network, Toronto, University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)

Conditions

CarcinomaCarcinoma, HepatocellularHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaKidney NeoplasmsMetastatic Renal Cell CarcinomaNeoplasmsNon-Small Cell Lung Cancer

Phase 1

Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

CompletedNCT00447005

PfizerCarcinoma

Start: 2007-02-28End: 2009-08-31Updated: 2012-05-23

A Study In Patients With Advanced Solid Tumor

CompletedNCT00726752

PfizerNeoplasms

Start: 2008-07-31End: 2010-04-30Updated: 2012-05-23

A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)

CompletedNCT02493751

PfizerRenal Cell Cancer

Start: 2015-10-26End: 2021-03-04Updated: 2022-02-18

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

CompletedNCT03289533

PfizerCarcinoma, Hepatocellular

Start: 2017-09-08End: 2019-10-25Updated: 2020-09-04

Phase 2

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

CompletedNCT01210495

PfizerHepatocellular Carcinoma

Start: 2010-12-06End: 2016-12-20Updated: 2019-01-09

Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma

CompletedNCT01334112

University Health Network, TorontoHepatocellular Carcinoma

Start: 2011-01-31End: 2018-03-31Updated: 2019-12-12

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

TerminatedNCT01441414

PfizerMetastatic Renal Cell Carcinoma

Start: 2011-11-21End: 2014-03-27Updated: 2019-01-08

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

CompletedNCT01469546

University of Michigan Rogel Cancer CenterHead and Neck Squamous Cell Carcinoma

Start: 2012-01-31End: 2016-03-31Updated: 2016-08-29

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

CompletedNCT01967576

National Cancer Institute (NCI)Paraganglioma, Pheochromocytoma

Start: 2013-10-19End: 2020-12-01Updated: 2021-01-06

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

TerminatedNCT03472560

PfizerNon-Small Cell Lung Cancer, Urothelial Cancer

Start: 2018-05-02End: 2023-02-09Updated: 2024-04-09

Phase 3

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

CompletedNCT00678392

PfizerKidney Neoplasms

Start: 2008-09-03End: 2016-02-25Updated: 2019-01-09

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

CompletedNCT00920816

PfizerKidney Neoplasms

Start: 2009-08-25End: 2021-04-29Updated: 2022-05-06

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

CompletedNCT02684006

PfizerRenal Cell Cancer

Start: 2016-03-23End: 2024-06-26Updated: 2025-07-30

Related Papers

Cardiac Biomarkers in Patients With Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.

2026-03-30

Real-world effectiveness and safety of avelumab + axitinib combination in first-line treatment of UK patients with advanced renal cell carcinoma

ESMO Real World Data and Digital Oncology2025-11-06

8The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinoma

The Oncologist2025-10-01

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.

Journal of Clinical Oncology2025-05-282 citations

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

2024-12-1822 citations

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response

Cell Reports Medicine2024-11-2516 citations

Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.

Journal of Clinical Oncology2024-06-0126 citations

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

BMJ Oncology2024-06-018 citations

189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy

Regular and Young Investigator Award Abstracts2023-10-31

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.

2023-10-1615 citations

Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma

Future Oncology2023-08-012 citations

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.

2023-05-028 citations

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

ESMO Open2023-04-2551 citations

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study

Pharmaceuticals2023-04-208 citations

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.

Journal of Clinical Oncology2023-02-20

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial

The Oncologist2022-12-2813 citations

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.

Journal of Clinical Oncology2022-06-013 citations

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Clinical Cancer Research2021-11-1732 citations

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment

Meditsinskiy sovet = Medical Council2021-06-12

Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Journal of Clinical Oncology2021-05-2018 citations

47 more papers not shown